Abstract

The present disclosure provides an apparatus for radiotherapy. The apparatus includes at least one first radiation source configured to provide one or more ultra-high dose rate charged particle beams; at least one second radiation source configured to provide one or more intensity-modulated beams; and a controller. The controller is configured to control the at least one first radiation source to generate the one or more ultra-high dose rate charged particle beams and control the at least one second radiation source to generate the one or more intensity-modulated beams such that the one or more ultra-high dose rate charged particle beams and the one or more intensity-modulated beams provide a substantially uniform total dose distribution across the target region.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The present invention relates to pharmaceutical products and in particular to pharmaceutical combination products. The invention further relates to uses of such products in medical treatment. Embodiments of the invention have been particularly developed as pharmaceutical combination products of an inhibitor of a tyrosine kinase and an autophagy inducer, preferably for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the use of BMMF Rep-protein as diagnostic marker for pancreatic cancer and diabetes.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones

Abstract

The present invention relates to the use of BMMF Rep-protein as a diagnostic marker for lung cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides a method for diagnosing and monitoring MS on the basis of an immunoassay using MSBI1.176 or MSBI2.176 Rep protein or fragments thereof as an antigen for binding antibodies against MSBI1.176 or MSBI2.176 Rep protein from a subject's sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/28 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving peroxidase
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention provides a method for upstream optimization the large-scale parvovirus production, preferably the oncolytic protoparvovirus H-1 (H-1PV). It is based on microcarriers or macrocarriers and their respective use in suspension or fixed-bed, an optimized cell culture medium, and a medium exchange strategy. In summary, with the optimized cell culture medium and the new medium exchange strategy, the inventors established a reduction in seeded cell density and animal serum, leading to an animal serum-free harvest. The tested carriers are best suited for a high H-1PV yield, cell growth, and bead-to-bead transfer capability, wherein the inventors additionally scaled up the process from 24-well plates to Erlenmeyer, Spinner flask and iCellis nano. As a conclusion, the present invention provides a large-scale method for producing the oncolytic protoparvovirus H-1 with a high virus yield, while lowering production costs and avoiding undesired products of animal origin at the same time.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01D 61/14 - UltrafiltrationMicrofiltration
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Goods & Services

Educational instruction; Providing of training and services of an academy in the field of oncology; Running seminars in the field of oncology; Provision of training courses; Conducting of seminars and congresses in the following fields: Oncology.

Abstract

The present invention covers MAP4K1 inhibitor compounds of formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for treatment, amelioration or prevention of neoplastic or abnormal cell proliferative disorders, such as cancer, conditions with dysregulated immune response, other disorders associated with aberrant Map4K1 signaling, or amelioration of vaccine therapies or cell therapies, as a sole agent or in combination with other active ingredients.

IPC Classes  ?

• C07D 487/20 - Spiro-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems

Abstract

The present invention relates to a multiplexed method for the quantification of antibodies in a plurality of samples, said antibodies being capable of binding to an antigen of interest in a plurality of samples, wherein each of the plurality of samples is in a separate vessel or well or a multi-well plate comprising (a) contacting each of the plurality of samples with yeast cells carrying a yeast-surface display expression cassette in its genome, wherein the yeast-surface display expression cassette encodes a fusion protein comprising the antigen of interest being fused to a cell wall or plasma membrane anchored protein of yeast, and wherein the cells for each sample of the plurality of samples can be distinguished from all other cells from all other of the plurality of samples by a unique DNA barcode being present in the cells for each sample, (b) separating the yeast cells from the sample, preferably by centrifugation, or filtration or magnetic beads that bind to the surface of the yeast cells, (c) contacting the yeast cells with a fluorescently labelled antibody binding to antibodies bound to the antigen of interest, (d) pooling the yeast cells after step (b) or (c), preferably after step (c), (e) sorting the yeast cells into different sub-pools based on the fluorescent intensity of each fluorescently-labeled yeast cell, wherein the fluorescent intensity of each cell is proportional to the number of antibodies being bound to the antigen of interest on the surface of the cell and optionally growing the sub-pools of cells,, (f) isolating the DNA from the yeast cells in each sub-pool, (g) subjecting the isolated DNA of each sub-pool to sequencing of each of the unique DNA barcodes, thereby quantifying the relative frequency of individual barcodes in each sub-pool and thereby identifying the samples being present in each of the subpools, and (h) quantifying the abundance of antibodies bound to the antigen of interest in each of the plurality of samples based on the mean fluorescent intensity measured for each yeast cell population expressing the antigen of interest and carrying a unique barcode, according to the distribution of the barcodes across the different fluorescent intensity bins for each sample, wherein the mean fluorescent intensity is proportional to the abundance of antigen-specific antibodies being present in each sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

An automated system (112) for providing at least one sample (136) for electrospray ionization in a mass spectrometer system (110) is disclosed. The automated system (112) comprises: •at least one electrospray emitter (122) comprising at least one emitter end (120) having at least one emitter tip (124) and at least one fluid-entrance end (126); •at least one autosampler (132), wherein the autosampler (132) comprises at least one autosampler outlet (134), wherein the autosampler (132) is configured for providing at least one sample (136) having at least one analyte; •at least one pipe (138) having at least one pipe fluid-outlet end (142) and at least one pipe fluid-inlet end (144), wherein the pipe fluid-inlet end (144) is fluidically connected to the autosampler outlet (134); •at least one liquid junction (146), wherein the liquid junction (146) comprises at least one connecting element (148) being made of at least one electrically conductive material, wherein the connecting element (148) receives the fluid-entrance end (126) of the electrospray emitter (122) and the pipe fluid-outlet end (142) of the pipe (138) such that a fluid connection between the electrospray emitter (122) and the pipe (138) is established, wherein the connecting element (148) is electrically connectable to at least one voltage source; wherein the emitter tip (124) comprises an opening having a diameter of 1 μm to 10 μm.

IPC Classes  ?

• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

The invention relates to a method for treating a chitin containing material comprising (i) milling the chitin containing material, (ii) contacting the milled chitin containing material from step (i) with a mixture comprising an aqueous solution of an organic acid, and (iii) contacting the chitin containing material with an alkaline solution comprising water:glycerol in a ratio of 0-100:1-50 (v/v) and potassium hydroxide at a concentration of from 0.2M to 5M; thereby treating the chitin containing material. The invention also relates to a chitin preparation, a calcium salt of an organic acid, a protein product, or an astaxanthin produced or producible from chitin containing material according to the inventive method and to the use of the produced or producible chitin preparation in manufacture of a natural or synthetic polymer, in agriculture, in packaging, in construction, or in environmental protection, as an ingredient in the production of a medicament, a food, or a cosmetics, and/or as a solidified enzyme carrier.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08B 37/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof

Abstract

The present invention relates to a method of determining the supplier from which a test animal-derived product sample originates, the method comprising the steps of: (a) determining a test methylation profile of one or more pre-selected methylation sites within the genomic material contained in the test animal-derived product sample; and (b) comparing the test methylation profile determined in (a) with a panel of predetermined reference methylation profiles of the same biological taxon of the test animal from which the product sample derives, wherein each of the predetermined reference methylation profiles is from a different reference animal and/or different supplier, wherein if the test methylation profile of (a) is significantly similar to one of the predetermined reference methylation profiles, the test animal-derived product sample is confirmed of originating from a first supplier from which a first reference animal with the predetermined reference profile is obtained.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Goods & Services

Erziehung und Unterricht, Ausbildung, sportliche und kulturelle Aktivität; Mikroverfilmung; Organisieren und Veranstalten von Konferenzen, Kongressen, Seminaren, Symposien, Kolloquien und Workshops im Bereich der Krebsprävention, Krebsfrüherkennung, Krebsdiagnostik, Krebsforschung, Krebsbehandlung, Gesundheitspflege, der Medizin sowie der Arzneimittelforschung und -anwendung; Gesundheitsschulung, -Personalentwicklung durch Aus- und Fortbildung von Medizinern und Naturwissenschaftlern auf dem Gebiet der Molekularbiologie, Immunologie und Onkologie; Gesundheitsschulung, Gesundheits-Veranstaltung und Durchführung von Workshops (Ausbildung) sowie Seminaren im Bereich der Krebsbehandlung, der Krebsforschung, der Gesundheitspflege, der Medizin sowie der Arzneimittelforschung und Fitnesstraining; Veröffentlichung von Informationen über Krebsdiagnostik, Krebstherapie, Krebsnachsorge, Krebsvorbeugung, Krebsfrüherkennung; Veröffentlichung von Informationen im Hinblick auf mit der Erkrankung Krebs zusammenhängenden sozialrechtlichen und gesellschaftlichen Fragen in Printmedien, in audiovisuellen Medien und im Internet. Wissenschaftliche und technologische Dienstleistungen sowie Forschungsarbeiten und diesbezügliche Designerdienstleistungen; Industrielle akademische Analyse- und industrielle Forschungsdienstleistungen; wissenschaftliche Forschung zu medizinischen Zwecken, Biologische Forschung, Design von computersimulierten Modellen, Forschung im Bereich der künstlichen Intelligenz, Forschung auf dem Gebiet der Bakteriologie, klinische Versuchsreihen, Kultivierung von Zellen für die wissenschaftliche Forschung, medizinische Forschung, wissenschaftliche Labordienstleistungen; Dienstleistung auf dem Gebiet der Krebsforschung; wissenschaftliche Forschung insbesondere im Bereich der Krebsprävention, der Krebsfrüherkennung, der Krebsbehandlung, der Krebsforschung, der Tumoranalytik, der Tumordiagnostik; Forschung auf dem Gebiet der Infektiologie und Bakteriologie; Physikalische Forschung; Dienstleistungen eines Chemikers, Dienstleistungen von chemischen Labors, Durchführung chemischer Analysen; Entwicklung von Computerplattformen; Erstellen von Programmen für die Datenverarbeitung; Erstellung und Entwurf von Website-gestützten Informationsverzeichnissen für Dritte [Dienstleistungen auf dem Gebiet der Informationstechnologie] Recherche- und Entwicklungsdienst bezüglich neuer Produkte für Dritte; Bewertung, Schätzung, Untersuchung und Gutachten im Bereich der Wissenschaft und der Technologie; Wissenschaftliche und industrielle Forschung; wissenschaftliche und medizinische Forschung und Entwicklung im Bereich der Biotechnologie bei Menschen und Tieren, einschließlich der Auftragsforschung Forschung auf dem Gebiet der Chemie; Durchführung wissenschaftlicher Untersuchungen und Studien im Bereich der Biotechnologie, der Medizin, der Krebsprävention, der Krebsfrüherkennung, der Krebsbehandlung und Krebsnachsorge; Initiierung und Koordinierung und Durchführung klinischer und epidemiologischer Studien; Analyse neuer klinischer Ansätze im Bereich der Krebsprävention, der Krebsfrüherkennung, der Krebsbehandlung und Krebsnachsorge; Forschung im Bereich künstlicher Intelligenz. Klinische Forschung, biomedizinische Forschung, pharmazeutische Forschung, genetische Forschung, bakteriologische Forschung und Analyse, biologische Forschung und Analyse, biotechnologische Forschung und Analyse, psychologische Forschung, Dienstleistungen eines Forschungslabors, Forschung im Bereich der Gentherapie, Beratungsleistungen zur Gentherapieforschung, Blutanalyse für wissenschaftliche Forschungszwecke, Durchführung von Toxizitätstests für Forschungszwecke, DNA-Überprüfung für wissenschaftliche Forschungszwecke, Vorbereitung biologischer Proben zu Forschungszwecken, Bereitstellung wissenschaftlicher Forschungsinformationen und Forschungsergebnisse über eine online durchsuchbare Datenbank, Forschung auf dem Gebiet der Molekularwissenschaft, Forschung und Entwicklung im Bereich Impfstoffe, Forschung und Entwicklung im Bereich Antikörpertechnologie, Durchführung von Analysen von menschlichem Gewebe für die medizinische Forschung. Medizinische Dienstleistungen; Gesundheits- und Schönheitspflege für Menschen; Dienstleistung von Kliniken; Beratung in der Pharmazie; medizinische Beratung; Dienstleistungen von Polikliniken, Krebs Vorsorgeuntersuchungen; Psychologische Dienstleistungen; Telemedizindienste; Dienstleistungen einer Gewebebank für menschliche Gewebe, Dienstleistungen eines Arztes, Dienstleistungen eines Krankenhauses, Dienstleistungen eines Psychologen, Dienstleistungen von Gesundheitszentren, Dienstleistungen von Hospizen zur Pflege und Betreuung Sterbender, Dienstleistungen von Kliniken [Ambulanzen], Gesundheitsberatung, Gesundheitspflegedienste, Krankenpflegedienste, Beratungen in der Pharmazie , medizinische Analysedienstleistungen zu Diagnose- und Behandlungszwecken durch medizinische Labore, medizinisches Screening, Palliativpflege, Therapiedienste, Dienstleistung auf dem Gebiet der Krebsprävention sowie der Krebsfrüherkennung; Beratung von Bürgern über Krebsdiagnostik, Krebstherapie, Krebsnachsorge, Krebsvorbeugung, Krebsfrüherkennung und allen mit der Krebserkrankung zusammenhängenden sozialen Fragen, nämlich psychosoziale Beratung; Durchführung von Informations- und Aufklärungsveranstaltungen im Bereich Krebsprävention sowie Krebsfrüherkennung; Bereitstellung von Informationen über Krebsdiagnostik, Krebstherapie, Krebsnachsorge, Krebsvorbeugung in Datenbanken oder anderen Datenverarbeitungsanlagen; Vermittlung von Informationsmaterial hinsichtlich der Krebsvorsorge, Krebsfrüherkennung und Krebsaufklärung; Beratung zur Tabakprävention; Gesundheitsberatung, Beratung mit Bezug zu Sport und Fitness, Ernährungsberatung, Zurverfügungstellung von Informationen bezüglich Diät und Ernährungsberatung, radiologische Dienstleistungen.

Goods & Services

Erziehung und Unterricht, Ausbildung, sportliche und kulturelle Aktivität; Mikroverfilmung; Organisieren und Veranstalten von Konferenzen, Kongressen, Seminaren, Symposien, Kolloquien und Workshops im Bereich der Krebsprävention, Krebsfrüherkennung, Krebsdiagnostik, Krebsforschung, Krebsbehandlung, Gesundheitspflege, der Medizin sowie der Arzneimittelforschung und -anwendung; Gesundheitsschulung, -Personalentwicklung durch Aus- und Fortbildung von Medizinern und Naturwissenschaftlern auf dem Gebiet der Molekularbiologie, Immunologie und Onkologie; Gesundheitsschulung, Gesundheits-Veranstaltung und Durchführung von Workshops (Ausbildung) sowie Seminaren im Bereich der Krebsbehandlung, der Krebsforschung, der Gesundheitspflege, der Medizin sowie der Arzneimittelforschung und Fitnesstraining; Veröffentlichung von Informationen über Krebsdiagnostik, Krebstherapie, Krebsnachsorge, Krebsvorbeugung, Krebsfrüherkennung; Veröffentlichung von Informationen im Hinblick auf mit der Erkrankung Krebs zusammenhängenden sozialrechtlichen und gesellschaftlichen Fragen in Printmedien, in audiovisuellen Medien und im Internet. Wissenschaftliche und technologische Dienstleistungen sowie Forschungsarbeiten und diesbezügliche Designerdienstleistungen; Industrielle akademische Analyse- und industrielle Forschungsdienstleistungen; wissenschaftliche Forschung zu medizinischen Zwecken, Biologische Forschung, Design von computersimulierten Modellen, Forschung im Bereich der künstlichen Intelligenz, Forschung auf dem Gebiet der Bakteriologie, klinische Versuchsreihen, Kultivierung von Zellen für die wissenschaftliche Forschung, medizinische Forschung, wissenschaftliche Labordienstleistungen; Dienstleistung auf dem Gebiet der Krebsforschung; wissenschaftliche Forschung insbesondere im Bereich der Krebsprävention, der Krebsfrüherkennung, der Krebsbehandlung, der Krebsforschung, der Tumoranalytik, der Tumordiagnostik; Forschung auf dem Gebiet der Infektiologie und Bakteriologie; Physikalische Forschung; Dienstleistungen eines Chemikers, Dienstleistungen von chemischen Labors, Durchführung chemischer Analysen; Entwicklung von Computerplattformen; Erstellen von Programmen für die Datenverarbeitung; Erstellung und Entwurf von Website-gestützten Informationsverzeichnissen für Dritte [Dienstleistungen auf dem Gebiet der Informationstechnologie] Recherche- und Entwicklungsdienst bezüglich neuer Produkte für Dritte; Bewertung, Schätzung, Untersuchung und Gutachten im Bereich der Wissenschaft und der Technologie; Wissenschaftliche und industrielle Forschung; wissenschaftliche und medizinische Forschung und Entwicklung im Bereich der Biotechnologie bei Menschen und Tieren, einschließlich der Auftragsforschung Forschung auf dem Gebiet der Chemie; Durchführung wissenschaftlicher Untersuchungen und Studien im Bereich der Biotechnologie, der Medizin, der Krebsprävention, der Krebsfrüherkennung, der Krebsbehandlung und Krebsnachsorge; Initiierung und Koordinierung und Durchführung klinischer und epidemiologischer Studien; Analyse neuer klinischer Ansätze im Bereich der Krebsprävention, der Krebsfrüherkennung, der Krebsbehandlung und Krebsnachsorge; Forschung im Bereich künstlicher Intelligenz. Klinische Forschung, biomedizinische Forschung, pharmazeutische Forschung, genetische Forschung, bakteriologische Forschung und Analyse, biologische Forschung und Analyse, biotechnologische Forschung und Analyse, psychologische Forschung, Dienstleistungen eines Forschungslabors, Forschung im Bereich der Gentherapie, Beratungsleistungen zur Gentherapieforschung, Blutanalyse für wissenschaftliche Forschungszwecke, Durchführung von Toxizitätstests für Forschungszwecke, DNA-Überprüfung für wissenschaftliche Forschungszwecke, Vorbereitung biologischer Proben zu Forschungszwecken, Bereitstellung wissenschaftlicher Forschungsinformationen und Forschungsergebnisse über eine online durchsuchbare Datenbank, Forschung auf dem Gebiet der Molekularwissenschaft, Forschung und Entwicklung im Bereich Impfstoffe, Forschung und Entwicklung im Bereich Antikörpertechnologie, Durchführung von Analysen von menschlichem Gewebe für die medizinische Forschung. Medizinische Dienstleistungen; Gesundheits- und Schönheitspflege für Menschen; Dienstleistung von Kliniken; Beratung in der Pharmazie; medizinische Beratung; Dienstleistungen von Polikliniken, Krebs Vorsorgeuntersuchungen; Psychologische Dienstleistungen; Telemedizindienste; Dienstleistungen einer Gewebebank für menschliche Gewebe, Dienstleistungen eines Arztes, Dienstleistungen eines Krankenhauses, Dienstleistungen eines Psychologen, Dienstleistungen von Gesundheitszentren, Dienstleistungen von Hospizen zur Pflege und Betreuung Sterbender, Dienstleistungen von Kliniken [Ambulanzen], Gesundheitsberatung, Gesundheitspflegedienste, Krankenpflegedienste, Beratungen in der Pharmazie , medizinische Analysedienstleistungen zu Diagnose- und Behandlungszwecken durch medizinische Labore, medizinisches Screening, Palliativpflege, Therapiedienste, Dienstleistung auf dem Gebiet der Krebsprävention sowie der Krebsfrüherkennung; Beratung von Bürgern über Krebsdiagnostik, Krebstherapie, Krebsnachsorge, Krebsvorbeugung, Krebsfrüherkennung und allen mit der Krebserkrankung zusammenhängenden sozialen Fragen, nämlich psychosoziale Beratung; Durchführung von Informations- und Aufklärungsveranstaltungen im Bereich Krebsprävention sowie Krebsfrüherkennung; Bereitstellung von Informationen über Krebsdiagnostik, Krebstherapie, Krebsnachsorge, Krebsvorbeugung in Datenbanken oder anderen Datenverarbeitungsanlagen; Vermittlung von Informationsmaterial hinsichtlich der Krebsvorsorge, Krebsfrüherkennung und Krebsaufklärung; Beratung zur Tabakprävention; Gesundheitsberatung, Beratung mit Bezug zu Sport und Fitness, Ernährungsberatung, Zurverfügungstellung von Informationen bezüglich Diät und Ernährungsberatung, radiologische Dienstleistungen.

Abstract

The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to therapeutically and diagnostically useful immunogenic peptides. In particular, the invention relates to an immunogenic peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 169, wherein the immunogenic peptide is inducible by DNA methyltransferase inhibitors and/or histone deacetylase transferase inhibitors. Further the invention relates to an isolated HLA protein which presents in its binding pocket the immunogenic peptide, a polynucleotide encoding the immunogenic peptide, a vector comprising the polynucleotide, a host cell comprising the immunogenic peptide, the isolated HLA protein, the polynucleotide, or the vector, a CD8+T cell which is capable of specifically recognizing via its T cell receptor (TCR) protein the immunogenic peptide, the isolated HLA protein or the host cell, a genetically engineered T cell expressing a chimeric antigen receptor protein (CAR T cell) which is capable of recognizing the immunogenic peptide, the isolated HLA protein or the host cell, a TCR protein which is capable of recognizing the immunogenic peptide, the isolated HLA protein or the host cell, and a chimeric antigen receptor (CAR) protein which is capable of recognizing the immunogenic peptide, the isolated HLA protein or the host cell. The present invention concerns therapeutic uses of the immunogenic peptide, the isolated HLA protein, the polynucleotide, the vector, the host cell, the CD8+ T cell, the CAR T cell, the TCR protein or the CAR protein as well as diagnostic uses of the immunogenic peptide of the invention, a nucleic acid encoding the immunogenic peptide of the invention or the isolated HLA protein. Moreover, the invention relates to a diagnostic device and a kit. The invention also refers to a method for identifying immunogenic peptides, in particular treatment-induced novel polyadenylated transcripts (TINPATs)-derived immunogenic peptides, suitable for the purposes envisaged in accordance with the present invention.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors

Abstract

The present invention relates to a binding compound binding to a mutein of H3 histone A (H3, HGNC:4764) comprising the amino acid sequence of SEQ ID NO:1 (H3 mutein), wherein said binding compound is a human antibody or a fragment and/or a derivative thereof, and to polynucleotides, host cells, medical uses and methods related thereto.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The invention relates to a method for assessing a therapeutic efficacy of a T cell. In embodiments, the method comprises providing a sample comprising one or more T cells, and determining for the one or more T cells an expression level of at least CD39, wherein said expression level is indicative of therapeutic efficacy. The invention further relates to a method for the prognosis, prediction, risk assessment and/or risk stratification of responsiveness of a subject having or suspected of having a cancer to a treatment with a therapeutic T cell population. The invention further relates to a method for enhancing a therapeutic efficacy of, or for selecting T cells to produce a therapeutically effective T cell population. Expression levels of CD39, and optionally additionally CD27, CD45RA and/or HLADR are preferred. The invention further relates to T cell population comprising therapeutic CD4+ and/ or CD8+ CAR-T cells, defined by percentages of cells with the said marker profiles. The invention further relates to a kit for carrying out the said method.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention relates to an inhibitor of intracellular copper-zinc-superoxide dismutase for use in protecting a subject from injury by a radiation burst. The present invention also relates to a kit comprising an SOD1 inhibitor and a radiosensitizer of cancer cells, to an in vitro use of an SOD1 inhibitor for protecting non-cancer cells from ionizing radiation, and to methods, compositions, and uses related thereto.

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 39/00 - General protective or antinoxious agents
• A61P 39/04 - Chelating agents

Abstract

The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site: b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based on the biological state of the nucleotide sequence of the first polymer, wherein the classification algorithm is trained based on the at least one target gene site and biological state data pertaining to cancer types.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16B 40/20 - Supervised data analysis

Abstract

The present invention relates to a modulator of wnt activity (wnt modulator) for use in treating a glioma in a subject, wherein cancer cells of said glioma were allocated to a multitude of lineage subpopulations, and to methods, databases, and uses related thereto.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to an in vitro method for producing an immunoreactive agent against human cancer cells infected with HPV16-related virus, said method comprising expressing an at least partial nucleic acid sequence encoding an immunoreactive agent obtained from an immune cell stimulated by a complex comprising a human leukocyte antigen (HLA) and a stimulation peptide (stimulation complex), wherein said stimulation peptide (i) consists of an amino acid sequence selected from SEQ ID NOs: l and 2 and said HLA is from HLA supertype HLA-A01; (ii) consists of an amino acid sequence of SEQ ID NO: 11 and said HLA is from HLA supertype HLA-A02, (iii) consists of an amino acid sequence selected from SEQ ID NOs:34 to 37 and said HLA is from HLA supertype HLA-A03/A11; (iv) consists of an amino acid sequence selected from SEQ ID NOs:60 and bland said HLA is from HLA supertype HLA-A24; (v) consists of an amino acid sequence selected from SEQ ID NOs:61, 76, and 77 and said HLA is from HLA supertype HLA-B07; or (vi) consists of an amino acid sequence selected from SEQ ID NOs:61 and 85 to 92 and said HLA is from HLA supertype HLA-B15; and wherein an HPV16-derived peptide consisting of the same amino acid sequence as said stimulation peptide has been verified to be presented by human HPV16-positive cancer cells, and to methods and uses related thereto.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The present invention relates to a vaccine for use in therapeutic vaccination of a human subject against a human papillomavirus 16 (HPV16)-related virus, wherein said vaccine provides at least five discrete immunization peptides consisting of amino acid sequences selected from at least five of the following groups: (i) SEQ ID NOs: 1 to 10; (ii) SEQ ID NOs: 11 to 52; (iii) SEQ ID NOs:53 to 79; (iv) SEQ ID NOs: 71 and 80 to 96; (v) SEQ ID NOs:25, 81, and 97-106; and (vi) SEQ ID NOs: 9, 12, 23, 63, 81, 85, 101, and 107 to 131; wherein said vaccine is a human leukocyte antigen (HLA) universal vaccine for use in any human subject expressing at least one HLA of a HLA supertype selected from the list consisting of HLA-A01, HLA-A02, HLA-A03/A11, HLA-A24, HLA- B07, and HLA-B15, and wherein each of said at least five immunization peptides, when presented as an H LA-complex, activates human anti-immunization peptide T cells. The present invention also relates to kits, devices, and methods related thereto.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 35/00 - Antineoplastic agents
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to a vaccine against a human papillomavirus 16 (HPV16)-related virus providing at least six discrete immunization peptides consisting of the amino acid sequences of SEQ ID NOs:1 to 6, wherein said vaccine comprises a mixture of discrete peptides each comprising exactly one of said amino acid sequences; and to the vaccine for use in medicine and in eliciting an immune response in a human subject against HPV infection, as well as a kit related thereto.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The present invention relates to a fusion protein comprising (i) a binding protein that specifically binds to a cell-surface antigen on a target cell of interest, and (ii) a modified IL-15 protein wherein said modified IL-15 protein has an amino acid sequence being at least 70% identical to the amino acid sequence shown in SEQ ID NO: 1 and wherein said modified IL-15 protein has an amino acid substitution of L to E at a position corresponding to position 45 of SEQ ID NO: 1, an amino acid substitution of N to E at a position corresponding to position 72 of SEQ ID NO: 1, an amino acid substitution of E to Q at a position corresponding to position 93 of SEQ ID NO: 1; and/or an amino acid substitution of F to L at a position corresponding to position 103 of SEQ ID NO: 1. The present invention further contemplates a polynucleotide encoding the fusion protein, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide, the vector or expression construct or a non-human transgenic multicellular organism comprising the polynucleotide, vector or expression construct or the host cell. The present invention also relates to a method for the manufacture of a fusion protein and to a medicament comprising the fusion protein, the polynucleotide, the vector or expression construct or the host cell. Yet, the said fusion protein, the polynucleotide, the vector or expression construct or the host cell are provided for use in treating and/or preventing a disease or medical condition in a subject.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention concerns antisense oligonucleotides and methods for using the same. In particular, it relates to an antisense oligonucleotide having the following elements: 3' – A1 – B – A2 – D – A3 – 5', wherein A1 is a nucleotide sequence having a length of from 6 to 16 nucleotides; B is the nucleotide cytosine; A2 is a nucleotide sequence having a length of from 33 to 37 nucleotides; D is an internal loop-forming nucleotide sequence having a length of 4 nucleotides; and A3 is a nucleotide sequence having a length of from 10 to 20 nucleotides, wherein elements A1, A2 and A3 are contiguous nucleotide sequences that are complementary to a target nucleotide sequence, and wherein the cytosine of element B forms a base-pair mismatch with adenosine in the target nucleotide sequence upon hybridization of elements A1, A2 and A3 to the target nucleotide sequence. Furthermore, the present invention relates to an expression cassette comprising a promoter sequence driving the expression of a nucleotide encoding said antisense oligonucleotide. In addition, the present invention concerns a vector comprising a nucleic acid encoding said antisense oligonucleotide or at least said one expression cassette. The present invention further envisages use of said antisense oligonucleotide, said expression cassette or the vector for editing RNA in a cultured cell or in vitro, as well as a method for editing RNA comprising contacting the RNA to be edited in cultured cell or in vitro. Moreover, the present invention relates to a pharmaceutical composition comprising the antisense oligonucleotide, the expression cassette or the vector. Further encompassed is an antisense, an expression cassette or a vector for use in treating and/or preventing a disease or disorder associated with mutated RNA. The present invention also refers to a method for treating and/or preventing a disease associated with mutated RNA.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to an inhibitor of mitoferrin-2 for use in treating a cancer with reduced activity of mitoferrin-1 in a subject. The present invention also relates to a method for identifying an inhibitor of mitoferrin-2 comprising (a) contacting a (i) host cell with a reduced mitoferrin-1 activity and (ii) a host cell with a non-reduced mitoferrin-1 activity with a candidate inhibitor of mitoferrin-2. (b) determining growth and/or morphology of the host cells of step (a): (c) identifying an inhibitor of mitoferrin-2 if a growth arrest and/or abnormal morphology is/are detected in step (b) in the host cell having the reduced activity of mitoferrin-1 but not in the host cell with the non-reduced activity of mitoferrin-1. The present invention further relates to a method for identifying a subject susceptible to cancer treatment by an inhibitor of mitoferrin-2, comprising (A) determining mitoferrin-1 activity in a sample of said subject, preferably a sample of cancer cells, and (B) identifying a patient susceptible to cancer treatment by an inhibitor of mitoferrin-2 based on determining step (A).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention concerns the field of gene transfer. More specifically, the present invention relates to method for enhancing receptor-targeted gene transfer into a primary T-cell as a host cell said method comprising contacting a host cell comprised in a sample with a gene transfer vehicle comprising a targeting agent which specifically binds to CD3 and a nucleic acid of interest to be transferred into the host cell in the presence of a tyrosine kinase inhibitor which is capable of inhibiting the LCK tyrosine kinase in said host cell and cultivating said host cell culture obtained for a time and under conditions which allow for receptor-targeted gene transfer. The present invention also relates to a method for the preparation of a medicament as well as a medicament comprising a gene transfer vehicle comprising a targeting agent which specifically binds to CD3 and a nucleic acid of interest to be transferred into primary T-cells and a tyrosine kinase inhibitor which is capable of inhibiting the LCK tyrosine kinase in said primary T-cells. Furthermore, also relates to a tyrosine kinase inhibitor for use in receptor-targeted gene transfer into said primary T-cell in a subject being in need thereof, wherein said tyrosine kinase inhibitor is capable of inhibiting the LCK tyrosine kinase in a primary T-cell as a host cell or gene transfer vehicle for use in enhancing receptor-targeted gene transfer into said primary T-cell in a subject being in need thereof, wherein the gene transfer vehicle is used in combination with a tyrosine kinase inhibitor which is capable of inhibiting the LCK tyrosine kinase in a primary T-cell as a host cell.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/86 - Viral vectors

Abstract

The disclosure relates to immunological compositions (immunostimulants) based on nanoparticles as carrier for adjuvants, optionally in combination with antigens or epitopes, in particular for the use of the compositions for immunoprophylaxis or immunotherapy.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

The present invention relates to innovative protoparvoviruses (PV) expressing RNAi effectors, preferably shRNAs against the PD-L1 gene which display improved anticancer activity. These new viruses are based on the ΔH-1PVsilencer platform that consists of a protoparvovirus H-1PV featuring an in-frame deletion within the NS region (ΔH-1PV) and harbouring a shRNA expression cassette in which the expression of the shRNA is controlled by the H1 Polymerase III promoter. In this invention the inventors aimed to use the ΔH-1PVsilencer to silence the PD-L1 gene. PD1/PD-L1 negatively regulates T cell-mediated immune responses and serves as a mechanism for tumors to escape antigen-specific T cell immune responses. The present invention also provides cells or organisms comprising said parvovirus.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to a T cell-NK cell interaction inhibitor for use in improving in vivo persistence and/or activity of T cells. The present invention also relates to a method for producing a preparation of T cells from a cell population comprising T cells and known or suspected to comprise NK cells, to a method of identifying a subject amenable to treatment with a T cell-NK cell interaction inhibitor, to a method for identifying a T cell-NK cell interaction inhibitor, and to a use of a T cell-NK cell interaction inhibitor for expanding T cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention concerns the field of diagnostics and patient stratification for cancer therapy. In particular, it relates to a method for assessing a treatment response associated with immunotherapy in a subject in need thereof comprising the steps of determining hepatic auto-aggressive CD8 positive (+) PD-1 positive (+) T cells exhibiting traits of activation and exhaustion or CD8+ T cell precursors thereof in a sample of a subject in need of immunotherapy or in a data set comprising imaging data of a subject in need of immunotherapy, and assessing the treatment response associated with immunotherapy based on the presence, absence or abundance of said hepatic auto-aggressive CD8+ PD-1+ T-cells exhibiting traits of activation or exhaustion or CD8+ T cell precursors thereof. Further contemplated is a method for recommending immunotherapy for a subject or a method for treating a subject by immunotherapy. The present invention also provides a diagnostic device for carrying out the method of the present invention.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention concerns the diagnosis and assessment of juvenile myelomonocytic leukemia (JMML). In particular, it relates to a method of diagnosing JMML in a subject, the method comprising a) determining the amount of at least one biomarker present on or in hematopoietic stem and progenitor cells (HSPCs) in a biological sample, said at least one biomarker being selected from each of i) group I consisting of: CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD 164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI 1 A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, LPAR6, HLA-DQA1, HLA-DRB5, and CD34, and ii) group II consisting of: IGLL1, BEST1, EREG, SLC5A3, SELK, PRRG3, NINJ1, MGST1, and HLA-G, b) comparing the determined amount of step a) to a reference, and c) diagnosing JMML based on the comparison of step b). Furthermore, the present invention relates to a method of classifying a subject suffering from JMML into a JMML low- or high-risk group. In addition, the present invention concerns use of at least one biomarker present on or in HSPCs in a biological sample for diagnosing JMML into a JMML low- or high-risk group in a subject having or having a risk of developing JMML. Furthermore, the present invention relates to a kit for diagnosing JMML in a subject or classifying a subject suffering from JMML into a JMML low- or high-risk group. Also, the present invention concerns an inhibitory agent that specifically inhibits at least one biomarker selected from the group consisting of CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI 1 A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, LPAR6, HLA-DQA1, HLA-DRB5, CD34, IGLL1, BEST1, EREG, SLC5A3, SELK, PRRG3, NINJ1, MGST1, and HLA-G present on or in hematopoietic stem and progenitor cells (HSPCs) for use in treating and/or preventing JMML. The present invention further relates to a pharmaceutical composition for use in treating and/or preventing JMML comprising at least two inhibitory agents according to the invention. Finally, the present invention envisages a method of treating and/or preventing JMML.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to therapeutic proteins and medical uses thereof. The present invention relates to modified ACE2 protein having increased binding affinity for the SARS- CoV-2 spike protein compared to wildtype ACE2 protein, wherein said modified ACE2 protein is lacking enzymatic activity and is fused to (i) a modified Fc domain of human immunoglobulin, wherein the Fc domain has either enhanced immunostimulating activity (Fc+) or attenuated immunostimulating activity (Fc-) or (ii) a protein that specifically binds to T cells or further enhances immunostimulating activity. The invention also relates to a polynucleotide encoding the modified ACE2 protein of the present invention, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct, and a non-human transgenic organism comprising the polynucleotide or the vector or expression construct. Moreover, the present invention relates also to a method for the manufacture of a modified ACE protein according to the present invention and to a medicament comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention. Furthermore, the invention relates to medical uses of the modified ACE2 protein, the polynucleotide or the vector or expression construct in treating and/or preventing a disease or disorder associated with SARS-CoV-2 infection. Finally, the invention provides a kit comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention.

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)

Abstract

The present invention relates to an antibody that specifically binds to human L1CAM as specified in the claims, related nucleic acids, host cells and pharmaceutical compositions and related methods and uses.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a binding polypeptide comprising a first binding domain binding a transmembrane E3 ligase; and a second binding domain binding a disease-related polypeptide, wherein said first binding domain comprises a furin domain 1 and/or a furin domain 2 of an R-spondin (RSPO), wherein said first binding domain lacks wnt signaling activity and/or lacks bone morphogenetic protein (BMP) signal inhibiting activity; and to polynucleotides, host cells, medical uses, and methods related thereto.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to a rodent H-1 parvovirus variant capable of propagating and spreading through human tumor cells. In particular, the present invention relates to a parvovirus variant (H-1PV DR) that is based on wild-type H-1 PV but contains a 114-nucleotide internal deletion and a 55-nucleotide repeated motif towards the right-end terminus in the presence of full length of right-end ITRs. This variant displays improved anticancer activity. The present invention also relates to a pharmaceutical composition containing such a parvovirus variant as well as its use for the treatment of cancer.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• C12N 15/864 - Parvoviral vectors

Abstract

The present invention is related to a DNA methylation-based array comprising at least: a first plurality of distinct locations, each location having at least one probe molecule comprising a nucleic acid sequence complementary to a CpG site from a first plurality of CpG sites of a first animal species; and a second plurality of distinct locations, each location having at least one probe molecule comprising a nucleic acid sequence complementary to a CpG site from a second plurality of CpG sites of a second animal species, wherein the first and second animal species are each independently selected from the group consisting of virus, mammals, birds and aquatic animals, and - the mammal is at least one livestock or animal cell line; - the bird is at least one poultry; and - the aquatic animal is at least one crustacean, cephalopod or fish, and wherein the first plurality of CpG sites comprises at least 1000 CpG sites of the first animal species; and the second plurality of CpG sites comprises at least 1000 CpG sites of the second animal species.

IPC Classes  ?

• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present invention relates to compositions, methods, uses and kits for combination therapies involving immunotherapies, such as adaptive cell therapy, e.g., T cell therapy, and an oncolytic virus (particularly parvovirus H-1), for treating subjects with cancer. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the cancer is a solid tumor or a hematological malignancy.

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention concerns the field of antibodies. More specifically, it relates to an antibody which specifically binds to a hapten being fentanyl or a derivative thereof, said antibody binding to the hapten with an equilibrium dissociation constant (Kd) of at most 1.000 pM, at most 800 pM, at most 600 pM, at most 400 pM, at most 200 pM, at most 100 pM or at most 75 pM, wherein the binding pocket for the hapten comprises amino acids from all three complementary determining regions (CDRs) of each chain. The present invention also relates to a polynucleotide encoding said antibody, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct or a non-human transgenic organism comprising said polynucleotide or said vector or expression construct. The invention also relates to said antibody or said polynucleotide for use as a medicament for treating and/or preventing a disease or condition in a subject associated with administration fentanyl or a derivative thereof.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

The present invention relates to pharmaceutical products and in particular to pharmaceutical combination products. The invention further relates to uses of such products in medical treatment. Embodiments of the invention have been particularly developed as pharmaceutical combination products of a protoparvovirus and an antiviral benzimidazole derivative or a pharmaceutically acceptable salt or prodrug of the benzimidazole derivative for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/563 - ImmunoassayBiospecific binding assayMaterials therefor involving antibody fragments
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a method of certifying a test animal-derived product sample, the method comprising the steps of: (a) determining a test methylation profile of one or more pre-selected methylation sites within the genomic material obtained from the test animal derived product sample; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal from which the product sample is derived from, where the control animal is not slaughtered by a single cut across the throat severing both carotid arteries, both jugular veins, both vagus nerves, trachea and/or esophagus and/or the control animal is not bled to death wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal, is indicative of the test animal having been slaughtered by a single cut across the throat severing both carotid arteries, both jugular veins, both vagus nerves, trachea and/or oesophagus and/or of the test animal having been bled to death and the test animal-derived product is certified so, and wherein the pre-selected methylation sites are CpG sites selected from genes or regions of genomic DNA from the control and test animal that shows the highest degree of methylation variation during the training of the method.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention is related to a method of determining if a test animal and/or a test animal from which a product is derived has been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical, the method comprising: (a) determining a test methylation profile from the genomic material contained in a biological sample obtained from the test animal and/or the animal-derived product; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal, where the control animal was not treated and/or is not currently undergoing treatment with at least one antibiotic and/or veterinary chemical, wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal, is indicative of the test animal having been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical; and wherein the test animal is an aquatic animal; and the veterinary chemical is an anti-parasitic, an anti- viral, a feed additive, a water additive, a disinfectant, glutaraldehyde, and/ or formalin used in aquaculture.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure provides an apparatus (200) for sample handling, comprising: a fluid control device (210) having an internal and/or external volume, the fluid control device (210) being connectable to a sample storage device (100) containing a content of a sequence of samples (S1-S4) separated by a separation medium (SM), the fluid control device (210) being further connectable to a sample analysis system (10) configured for sample analysis; a pump device (220) connected to the fluid control device (210) and configured to transport the content of the sample storage device (100) into the internal and/or external volume of the fluid control device (210); a detection device (230) at the sample storage device (100) and configured to distinguish between the samples (S1-S4) and the separation medium (SM) when the content is transported into the internal and/or external volume of the fluid control device (210); and a controller configured to operate the pump device (220) and the fluid control device (210) based on a detection signal received from the detection device (230).

IPC Classes  ?

• G01N 35/08 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a stream of discrete samples flowing along a tube system, e.g. flow injection analysis
• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices

Abstract

The invention is based on the finding that endoplasmic reticulum (ER) stress signalling is associated with the pathogenesis of liver disorders such fatty liver, cirrhosis and hepatocellular carcinoma (HCC), and others. The invention identifies novel targets for liver disease therapy which are involved in ER stress signalling, and thereby pertains to compounds and compositions for medical uses, screening approaches to identify therapeutics as well as diagnostic approaches for the identification of disorders or the stratification of certain liver disease patient groups. The invention also pertains to the use of immune checkpoint inhibitors in combination with the compounds or compositions and/or in the treatment of endoplasmic reticulum (ER) stress signalling induced liver cancers.

IPC Classes  ?

• A61K 38/55 - Protease inhibitors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to novel compounds that bind to the prostate-specific membrane antigen (PSMA)-binding and their use in the diagnosis and treatment of certain diseases where PSMA is upregulated.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 51/04 - Organic compounds

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 33/36 - ArsenicCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention concerns assessment of therapies for cancer and, in particular, hematopoietic cancers. In particular, it relates to a method for assessing and, preferably predicting response to a BCL-family inhibitor therapy in a subject suffering from cancer, preferably a hematopoietic cancer, comprising the steps of determining the amounts of the biomarkers BCL- 2, BCL-xL, and MCL-1 in a tumor driving cell population, preferably leukemic stem cell (LSC) population, in a sample of said subject and comparing the amounts of the said biomarkers to a reference, whereby the response to a BCL-family inhibitor therapy is assessed. Furthermore, the present invention relates to a BCL-2 inhibitor, preferably Venetoclax, a BCL-xL and/or MCL-1 inhibitor, preferably Navitoclax, or a BCL-2 inhibitor in combination with at least one MCL-1 inhibitor or use in treating cancer, preferably a hematopoietic cancer, in a subject that has been assessed to benefit from a therapy using said inhibitors by using the method of the invention.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to an inhibitor of a glutathione peroxidase 4 (GPX4) for use in treating and/or preventing cancer in a subject in combination with (i) a Bcl-2 inhibitor and a hypomethylating agent, or (ii) a glutaminolysis inhibitor and a transsulfuration inhibitor, and to combined preparations, kit, methods, and uses related thereto.

IPC Classes  ?

• A61K 33/36 - ArsenicCompounds thereof
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention generally relates to the field of dye labelled, preferably fluorescent dye labelled, radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof as well as their use in preoperative PET Imaging and Fluorescence-Guided Surgery of cancers, especially prostate cancer, and metastases thereof.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQ, the linker comprising at least one N-alkylated, preferably N-methylated amino acid.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths

Abstract

The present invention generally relates to the field of dye labelled, preferably fluorescent dye labelled, radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof as well as their use in preoperative PET Imaging and Fluorescence-Guided Surgery of cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q and a chelator residue A and a dye group Z a linker L1and a linker L2, the compound preferably having the structure Z-L2-A-L1-Q.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 49/00 - Preparations for testing in vivo
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof as well as to the use of said PSMA binding ligand, the PSMA binding ligand comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQii.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: —KQPAa; QPAKa; PAKQa; or AKQPa; —NPDPb; PNPDb; DPNPb; or PNPDb; —NANPc; ANPNc; NPNAc; or PNANc; —NVDPd; VDPNd; DPNVd; or PNVDd; and —NANPe; ANPNe; NPNAe; or PNANe. wherein a, b, c, d, and e are each independently 0 or greater and wherein a±b±c±d±e is at least 2; and a nanocage monomer peptide.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 37/04 - Immunostimulants
• C07K 14/445 - Plasmodium

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. In particular, the present invention relates to a PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q and a chelator residue A linked via at least one linker LAQ, the linker comprising at least one N-alkylated, preferably N-methylated amino acid.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Abstract

The present invention generally relates to the field of dye labelled, preferably fluorescent dye labelled, radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof as well as their use in preoperative PET Imaging and Fluorescence-Guided Surgery of cancers, especially prostate cancer, and metastases thereof.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 51/04 - Organic compounds
• A61K 103/30 - Rare earths
• A61K 103/34 - Gadolinium
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to the use of BMMF Rep-protein as a diagnostic marker for lung cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to the use of BMMF Rep-protein as diagnostic marker for pancreatic cancer and diabetes.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a binding polypeptide comprising a first variable T cell receptor (TCR) domain and a second variable TCR domain wherein (i) the complementarity determining region 3 (CDR3) of the first variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:1 or a sequence at least 80% identical thereto; and/or wherein the CDR3 of the second variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:2 or a sequence at least 80% identical thereto; or wherein (ii) the CDR3 of the first variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:3 or a sequence at least 80% identical thereto; and/or wherein the CDR3 of the second variable TCR domain comprises, preferably consists of, the amino acid sequence of SEQ ID NO:4 or a sequence at least 80% identical thereto; and to polynucleotides, host cells, methods, uses, kits, and devices related thereto.

IPC Classes  ?

• C07K 14/725 - T-cell receptors

Abstract

The present invention relates to a P2Y purinoceptor 2 (P2RY2) activity modulator for use in T cell immunotherapy. The present invention further relates to a polynucleotide encoding a P2RY2 activity modulator and to a host cell comprising the P2RY2 activity modulator for use in T cell immunotherapy. Furthermore, the present invention relates to a method of identifying 5 a subject amenable to T cell immunotherapy comprising (A) determining in a sample of said subject the activity of P2RY2; (B) comparing the activity determined in step (A) to a reference; and identifying a subject amenable to T cell immunotherapy based on the comparison of step (B), as well as to a method for identifying a P2RY2 activity modulator, said method comprising (I) contacting a host cell with a candidate compound suspected to be a P2RY2 activity 10 modulator; (II) determining B7-H3 activity in said host cell; (III) comparing the B7-H3 activity determined in step (II) to a control; and (IV) identifying a P2RY2 activity modulator based on the comparison in step (III).

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The present invention relates to a use of a labeling compound having a chemical structure of formula (I): (A)-x1-(B)-x2-(C), wherein (A) is at least one motif specifically binding to cell membranes of cancer cells; (B) at least one chelator moiety; (C) a dye moiety; x1 is a spacer covalently connecting (A) and (B); x2 is a spacer or a chemical single bond connecting (B) and (C), or a pharmaceutically acceptable salt thereof, as a labeling agent for detecting cancerous tissue in a subject, said use comprising administration of a labeling dose of said labeling compound to said subject; and to compounds for use, and methods related thereto.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 51/08 - Peptides, e.g. proteins
• A61K 51/04 - Organic compounds

Abstract

The present invention relates to a P2Y purinoceptor 2 (P2RY2) activity modulator for use in T cell immunotherapy. The present invention further relates to a polynucleotide encoding a P2RY2 activity modulator and to a host cell comprising the P2RY2 activity modulator for use in T cell immunotherapy. Furthermore, the present invention relates to a method of identifying 5 a subject amenable to T cell immunotherapy comprising (A) determining in a sample of said subject the activity of P2RY2; (B) comparing the activity determined in step (A) to a reference; and identifying a subject amenable to T cell immunotherapy based on the comparison of step (B), as well as to a method for identifying a P2RY2 activity modulator, said method comprising (I) contacting a host cell with a candidate compound suspected to be a P2RY2 activity 10 modulator; (II) determining B7-H3 activity in said host cell; (III) comparing the B7-H3 activity determined in step (II) to a control; and (IV) identifying a P2RY2 activity modulator based on the comparison in step (III).

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Described herein is malarial immunogen or a variant thereof comprising at least a portion of the wild-type PfCSP amino acid sequence lacking a KQ motif. In aspects, the malarial immunogen is lacking a KQP motif. For example, the immunogens described herein, in aspects, exclude the C-terminal domain of PfCSP. In other aspects, the immunogens described herein specifically exclude a KQ or KQP motif. In aspects the immunogens described herein exclude an N-terminal KQ or KQP motif, which is part of the N- terminal junction region in PfCSP.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 33/06 - Antimalarials
• A61P 37/04 - Immunostimulants
• C07K 14/445 - Plasmodium
• C12N 15/30 - Genes encoding protozoal proteins, e.g. from Plasmodium, Trypanosoma, Eimeria
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Described herein is malarial immunogen or a variant thereof comprising at least a portion of the wild-type PfCSP amino acid sequence lacking a KQ motif. In aspects, the malarial immunogen is lacking a KQP motif. For example, the immunogens described herein, in aspects, exclude the C-terminal domain of PfCSP. In other aspects, the immunogens described herein specifically exclude a KQ or KQP motif. In aspects the immunogens described herein exclude an N-terminal KQ or KQP motif, which is part of the N- terminal junction region in PfCSP.

IPC Classes  ?

• C07K 14/445 - Plasmodium
• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 33/06 - Antimalarials
• A61P 37/04 - Immunostimulants
• C07K 19/00 - Hybrid peptides
• C12N 15/30 - Genes encoding protozoal proteins, e.g. from Plasmodium, Trypanosoma, Eimeria
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention concerns the development of vesicles that could be used for generation of vaccines or as compound delivery vehicles. More specifically, the invention relates to a method for preparing a vesicle comprising the steps of: providing recombinant Trypanosoma brucei cells expressing sortaggable VSG, treating said cells in hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed, isolating the cellular membranes from the solution, suspending the isolated membranes previously obtained in a isotonic solution, treating the suspended cellular membranes obtained in the previous step with sonication in order to obtain a vesicle suspension, removing aggregated membranous debris from the vesicle suspension previously obtained, separating the vesicle suspension into populations of vesicles, and providing vesicles from a population of vesicles which is characterized by the following parameters: (i) having a single predominant protein revealed after Coomassie staining an SDS PAGE that has an apparent molecular weight of 55 to 60 kDa, (ii) having a spherical appearance in electron micrographs and (iii) exhibiting a homogenous surface structure in electron micrographs. Moreover, the present invention also relates to a vesicle comprising sortaggable VSG characterized by the aforementioned parameters as well as such a vesicle for use in treating and/or preventing a disease or medical condition or as a compound delivery vesicle, preferably, drug delivery vehicle, more preferably, nucleic acid delivery vesicle. Finally, the invention contemplates a kit for carrying out the method of the present invention comprising recombinant Trypanosoma brucei cells expressing sortaggable VSG and at least one agent for carrying out the method of the present invention or a kit comprising the vesicle of the present invention.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 39/385 - Haptens or antigens, bound to carriers

Abstract

The present invention concerns the development of vesicles that could be used for generation of vaccines or as compound delivery vehicles. More specifically, the invention relates to a method for preparing a vesicle comprising the steps of: providing recombinant Trypanosoma brucei cells expressing sortaggable VSG, treating said cells in hypotonic solution in the presence of at least one protease inhibitor until the cells are lysed, isolating the cellular membranes from the solution, suspending the isolated membranes previously obtained in a isotonic solution, treating the suspended cellular membranes obtained in the previous step with sonication in order to obtain a vesicle suspension, removing aggregated membranous debris from the vesicle suspension previously obtained, separating the vesicle suspension into populations of vesicles, and providing vesicles from a population of vesicles which is characterized by the following parameters: (i) having a single predominant protein revealed after Coomassie staining an SDS PAGE that has an apparent molecular weight of 55 to 60 kDa, (ii) having a spherical appearance in electron micrographs and (iii) exhibiting a homogenous surface structure in electron micrographs. Moreover, the present invention also relates to a vesicle comprising sortaggable VSG characterized by the aforementioned parameters as well as such a vesicle for use in treating and/or preventing a disease or medical condition or as a compound delivery vesicle, preferably, drug delivery vehicle, more preferably, nucleic acid delivery vesicle. Finally, the invention contemplates a kit for carrying out the method of the present invention comprising recombinant Trypanosoma brucei cells expressing sortaggable VSG and at least one agent for carrying out the method of the present invention or a kit comprising the vesicle of the present invention.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The present invention concerns the field of antibodies. More specifically, it relates to an antibody which specifically binds to a hapten being fentanyl or a derivative thereof, said antibody binding to the hapten with an equilibrium dissociation constant (Kd) of at most 1.000 pM, at most 800 pM, at most 600 pM, at most 400 pM, at most 200 pM, at most 100 pM or at most 75 pM, wherein the binding pocket for the hapten comprises amino acids from all three complementary determining regions (CDRs) of each chain. The present invention also relates to a polynucleotide encoding said antibody, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct or a non-human transgenic organism comprising said polynucleotide or said vector or expression construct. The invention also relates to said antibody or said polynucleotide for use as a medicament for treating and/or preventing a disease or condition in a subject associated with administration fentanyl or a derivative thereof.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 25/36 - Opioid-abuse
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

The present invention concerns the field of antibodies. More specifically, it relates to an antibody which specifically binds to a hapten being fentanyl or a derivative thereof, said antibody binding to the hapten with an equilibrium dissociation constant (Kd) of at most 1.000 pM, at most 800 pM, at most 600 pM, at most 400 pM, at most 200 pM, at most 100 pM or at most 75 pM, wherein the binding pocket for the hapten comprises amino acids from all three complementary determining regions (CDRs) of each chain. The present invention also relates to a polynucleotide encoding said antibody, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct or a non-human transgenic organism comprising said polynucleotide or said vector or expression construct. The invention also relates to said antibody or said polynucleotide for use as a medicament for treating and/or preventing a disease or condition in a subject associated with administration fentanyl or a derivative thereof.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 25/36 - Opioid-abuse

Abstract

The present invention relates to a method for the manufacture of an antibody which specifically binds to an antigen, preferably, being a hapten such as fentanyl or a derivative thereof, comprising the steps of a) contacting a B-cell sample of an animal, preferably a mouse, which has been immunized with the antigen with labeled antigen, b) isolating individual cells from that sample that are CD19 positive, are CD138 negative, having bound the labeled antigen, c) determining the nucleic acid sequences of a plurality of expressed genes, preferably, the entire transcriptome for each of said isolated individual cells, d) selecting individual memory B-cells among the individual isolated cells by identifying the presence of nucleic acid sequences of one or more expressed genes selected from the group consisting of: BhIhe41, Parm1, CD80, CobI, IgG1, Sspn, Ackr2, Nt5e, and Mki67 within the nucleic acid sequences of a plurality of expressed genes, e) assembling antibody light and heavy variable chain encoding nucleic acid sequences from the nucleic acid sequence of the plurality of expressed genes of the selected individual memory B-cells, and f) expressing the antibody light and heavy chain encoding nucleic acid sequences assembled in step e) in a host cell in order to manufacture the antibody.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 25/36 - Opioid-abuse
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The disclosure relates to a composition of nanoparticles as carrier for HPV-derived immunogenic fragments and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition and/or nanoparticles.

IPC Classes  ?

• C07K 14/025 - Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/20 - Antivirals for DNA viruses
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for the manufacture of an antibody which specifically binds to an antigen, preferably, being a hapten such as fentanyl or a derivative thereof, comprising the steps of a) contacting a B-cell sample of an animal, preferably a mouse, which has been immunized with the antigen with labeled antigen, b) isolating individual cells from that sample that are CD19 positive, are CD138 negative, having bound the labeled antigen, c) determining the nucleic acid sequences of a plurality of expressed genes, preferably, the entire transcriptome for each of said isolated individual cells, d) selecting individual memory B-cells among the individual isolated cells by identifying the presence of nucleic acid sequences of one or more expressed genes selected from the group consisting of: BhIhe41, Parm1, CD80, CobI, IgG1, Sspn, Ackr2, Nt5e, and Mki67 within the nucleic acid sequences of a plurality of expressed genes, e) assembling antibody light and heavy variable chain encoding nucleic acid sequences from the nucleic acid sequence of the plurality of expressed genes of the selected individual memory B-cells, and f) expressing the antibody light and heavy chain encoding nucleic acid sequences assembled in step e) in a host cell in order to manufacture the antibody.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 25/36 - Opioid-abuse
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention concerns the field of therapeutic and diagnostic antibodies against SARS-CoV-2. Specifically, the invention relates to an antibody which specifically binds to the receptor binding domain (RBD) of SARS-CoV-2 spike protein with an equilibrium dissociation constant (Kd) of less than 10-9 M. The present invention further relates to a polynucleotide encoding the antibody of the invention, a vector or expression construct comprising said polynucleotide, a host cell comprising said polynucleotide, vector or expression construct, or a non-human transgenic organism comprising the polynucleotide, vector or expression construct of the invention. Yet, the invention relates to a method for producing the antibody of the invention and to the use of the host cell of the invention for producing the antibody of the invention. Moreover, the preset invention provides for using an antibody, a polynucleotide or a vector of the invention for treating and/or preventing a disease or condition or for using the antibody for diagnosing said disease or condition. Finally, the invention relates to a kit for diagnosing SARS-CoV-2 infection in a subject.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a method for identifying an antibody that binds the SARS-CoV-2 spike protein with high affinity, the method comprising the steps of: (a) determining the presence of IGKV1-39 in the light chain and/or IGHV3-9 in the heavy chain of said antibody; and (b) identifying an antibody that binds the SARS-CoV-2 spike protein with high affinity if IGKV1-39 is present in its light chain and/or IGHV3-9 is present in its heavy chain. The present invention also relates to a method for manufacturing an antibody, a method for assessing whether a subject produces antibodies that bind the SARS-CoV-2 spike protein with high affinity, and to uses, kits, antibodies, and polynucleotides related thereto.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 31/14 - Antivirals for RNA viruses

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention pertains to a method for the identification of the geographic origin of an individual test subject or of an individual group of test subjects, the method comprising the comparison of a test methylation profile obtained from genomic material of the individual test subject or of the individual group of test subjects with one or more predetermined reference methylation profiles each being specific for a distinct geographic origin.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12Q 1/6869 - Methods for sequencing

Abstract

The present invention provides a method for diagnosing and monitoring MS on the basis of an immunoassay using MSBI1.176 or MSBI2.176 Rep protein or fragments thereof as an antigen for binding antibodies against MSBI1.176 or MSBI2.176 Rep protein from a subject's sample.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed herein are a method and apparatus for photoacoustic imaging (PAI) or ultrasound (US) imaging of biological tissue (18). The method comprises recording 2D-PAI and/or US images (46) of said biological tissue (18), each 2D-PAI or US image (46) being associated with a corresponding image plane (38), providing, prior to recording said 2D-PAI or US images (46) of said biological tissue (18), an optical pattern (28, 40) on or close to a surface of said biological tissue, said optical pattern (28, 40) comprising one or more optical dyes configured for absorbing light at a pattern-characteristic wavelength. The optical pattern (28, 40) is configured such that the location of the image plane (38) with respect to the optical pattern (28, 40) can be determined at least approximately from said representation of the optical pattern (28, 40) in said 2D-PAI image (46) and/or that the relative location of consecutively taken 2D-PAI images (46) with respect to each other can be at least approximately determined.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present disclosure provides an apparatus for radiotherapy. The apparatus includes at least one first radiation source configured to provide one or more ultra-high dose rate charged particle beams; at least one second radiation source configured to provide one or more intensity-modulated beams; and a controller. The controller is configured to control the at least one first radiation source to generate the one or more ultra-high dose rate charged particle beams and control the at least one second radiation source to generate the one or more intensity-modulated beams such that the one or more ultra-high dose rate charged particle beams and the one or more intensity-modulated beams provide a substantially uniform total dose distribution across the target region.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The present invention provides novel PSMA targeting urea-based ligands that binds to prostate-specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.

IPC Classes  ?

• A61K 51/04 - Organic compounds

Abstract

An automated system (112) for providing at least one sample (136) for electrospray ionization in a mass spectrometer system (110) is disclosed. The automated system (112) comprises: • at least one electrospray emitter (122) comprising at least one emitter end (120) having at least one emitter tip (124) and at least one fluid-entrance end (126); • at least one autosampler (132), wherein the autosampler (132) comprises at least one autosampler outlet (134), wherein the autosampler (132) is configured for providing at least one sample (136) having at least one analyte; • at least one pipe (138) having at least one pipe fluid-outlet end (142) and at least one pipe fluid-inlet end (144), wherein the pipe fluid-inlet end (144) is fluidically connected to the autosampler outlet (134); • at least one liquid junction (146), wherein the liquid junction (146) comprises at least one connecting element (148) being made of at least one electrically conductive material, wherein the connecting element (148) receives the fluid-entrance end (126) of the electrospray emitter (122) and the pipe fluid-outlet end (142) of the pipe (138) such that a fluid connection between the electrospray emitter (122) and the pipe (138) is established, wherein the connecting element (148) is electrically connectable to at least one voltage source; wherein the emitter tip (124) comprises an opening having a diameter of 1 μm to 10 μm.

IPC Classes  ?

• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

The present invention relates to an effector polypeptide comprising (i) an amino acid sequence at least 70% identical to the amino acid sequence RSNLGWLCLLLLPIPLIVWVKRK (SEQ ID NO: 1); and (ii) an exchange of an amino acid to a non-identical amino acid at least one position selected from the list consisting of positions 1, 2, 3, 19, 22, and 23 of the amino acid sequence of (i). The present invention also relates to a polynucleotide comprising a nucleic acid sequence encoding the aforesaid effector polypeptide, and to related host cells, pharmaceutical compositions, and uses, and to related uses in medicine, in particular in treating and/or preventing cancer, inflammatory disease, or acute or chronic neurodegenerative disease.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons

Abstract

The invention pertains to an immunization scheme for inducing or amplifying an immune response involving Variant Surface Glycoproteins as carriers for antigenic structures against which the immune response is targeted. The invention is based on a specific priming and boosting schedule using the array presented and soluble VSG variants. Surprisingly, the immunization scheme of the invention elicits a strong and long-lasting antibody response in the immunized subject and therefore is applicable in vaccination approaches, immunotherapy and in the production of novel antibodies.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to an immunoreactive molecule that specifically recognises and binds to human Ankyrin Repeat Domain-Containing Protein 30A (NY- BR-1) and, in particular, to an immunoreactive molecule, which shows no cross- reactivity to other human Ankyrin repeat domain containing proteins. The invention further relates to the use of such immunoreactive molecules in the treatment of cancer as well as in companion diagnostics methods.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/725 - T-cell receptors

Abstract

The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a method for upstream optimization the large-scale parvovirus production, preferably the oncolytic protoparvovirus H-1 (H-1PV). It is based on microcarriers or macrocarriers and their respective use in suspension or fixed-bed, an optimized cell culture medium, and a medium exchange strategy. In summary, with the optimized cell culture medium and the new medium exchange strategy, the inventors established a reduction in seeded cell density and animal serum, leading to an animal serum-free harvest. The tested carriers are best suited for a high H-1PV yield, cell growth, and bead-to-bead transfer capability, wherein the inventors additionally scaled up the process from 24-well plates to Erlenmeyer, Spinner flask and iCellis nano. As a conclusion, the present invention provides a large-scale method for producing the oncolytic protoparvovirus H-1 with a high virus yield, while lowering production costs and avoiding undesired products of animal origin at the same time.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 7/02 - Recovery or purification

Abstract

The present disclosure provides a computer implemented method for facilitating a teaching surgeon to teach or assist a learning surgeon in minimally invasive interventions using a surgical instrument including displaying endoscopic images of an intervention site in real time on a display device, said endoscopic images being captured using a camera associated with an endoscopic instrument, and tracking a movement of one or both hands of said teaching surgeon and/or a device held by said teaching surgeon, using a real-time tracking apparatus, wherein said real-time tracking apparatus comprises a tracking system and a computing device, wherein said tracking of said movement comprises recording a sequence of tracking information of one or both hands of said teaching surgeon and/or the device held by said teaching surgeon.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
• G06T 7/521 - Depth or shape recovery from laser ranging, e.g. using interferometryDepth or shape recovery from the projection of structured light
• G06T 7/10 - SegmentationEdge detection

Abstract

The present invention provides a method for upstream optimization the large-scale parvovirus production, preferably the oncolytic protoparvovirus H-1 (H-1PV). It is based on microcarriers or macrocarriers and their respective use in suspension or fixed-bed, an optimized cell culture medium, and a medium exchange strategy. In summary, with the optimized cell culture medium and the new medium exchange strategy, the inventors established a reduction in seeded cell density and animal serum, leading to an animal serum-free harvest. The tested carriers are best suited for a high H-1PV yield, cell growth, and bead-to-bead transfer capability, wherein the inventors additionally scaled up the process from 24-well plates to Erlenmeyer, Spinner flask and iCellis nano. As a conclusion, the present invention provides a large-scale method for producing the oncolytic protoparvovirus H-1 with a high virus yield, while lowering production costs and avoiding undesired products of animal origin at the same time.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Goods & Services

Software for the healthcare sector; Artificial intelligence software for healthcare; Artificial intelligence apparatus; Mobile apps for the healthcare sector; Cameras [photography]. Compilation of statistics; Marketing; Marketing research; Opinion polling; assembling data in computer-databases; Advertising; Providing addresses with regard to cancer screening and cancer information; Compilation of statistics relating to cancer prevention; Compilation of statistics relating to cancer screening; Marketing research in relation to cancer prevention and/or cancer screening; Opinion polling in relation to cancer prevention and/or cancer screening; Marketing in relation to cancer prevention and/or cancer screening; Public relations relating to cancer prevention, cancer early detection, cancer diagnosis, cancer research, cancer treatment. Education, teaching, providing of training, sporting and cultural activities; Organisation and arranging of conferences, congresses, seminars and workshops in the field of cancer prevention, cancer screening, cancer diagnosis, cancer research, cancer treatment, healthcare, medicine, medicine research and use; Education services relating to health, Health and fitness training; Publication of information relation to cancer diagnosis, cancer treatment, cancer aftercare, cancer prevention, cancer screening; Publication of information with regard to social law and social issues in connection with cancer in print media, in audiovisual media and on the internet; Microfilming; Consultancy in relation to the publication of audio, video, audiovisual and print media in the field of cancer research, and cancer prevention and cancer screening. Scientific and technological services and research and design relating thereto; Industrial academic analysis and industrial research services; Scientific research for medical purposes; Services in the field of cancer research; Scientific research in the field of cancer prevention, cancer screening, cancer treatment, cancer research, tumour analysis, tumour diagnosis; Biological research, research in the field of infectiology and bacteriology; Research in the field of physics; Research and development (for others); Environmental research services; Assessment, appraisal, investigation and surveying in the field of science and technology; Scientific and industrial research; Scientific and medical research and development in the field of biotechnology in human beings and animals, including contract research; Conducting of scientific examinations and studies in the field of biotechnology, medicine, cancer prevention, cancer screening, cancer treatment and cancer aftercare; Research in the field of chemistry; Chemistry services; Chemical analysis; Chemical laboratories; Design and development of software and apps in the healthcare sector; Development and implementation of research strategies; Initiation and coordination and conducting of clinical and epidemiological studies; Analysis of new clinical approaches in the field of cancer prevention, cancer screening, cancer treatment and cancer aftercare; research in the fields of artificial intelligence. Medical and healthcare services; Human hygiene and beauty care; Hospital services; Pharmacy advice; Medical clinics, Cancer health checks; Psychological services; Medical assistance; Medical analysis services for cancer diagnosis and prognosis; Services in the field of cancer prevention, cancer screening, cancer diagnostics, cancer therapy and cancer aftercare; Citizen's advice relating to cancer diagnostics, cancer therapy, cancer prevention, cancer screening; Psychosocial counselling; Conducting of information and awareness-raising events in the field of cancer prevention and cancer screening; Telemedical services; Medical information services provided via the Internet; Providing information relating to cancer diagnostics, cancer therapy, cancer aftercare, cancer prevention in databases or other data processing facilities; Providing of information material with regard to cancer prevention, cancer screening and cancer awareness; Tobacco use prevention consultancy; Health counselling, Sport and fitness consultancy, Dietetic advisory services, Providing information relating to dietary and nutritional guidance, Radiology services.

Abstract

The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a method of determining the supplier from which a test animal-derived product sample originates, the method comprising the steps of: (a) determining a test methylation profile of one or more pre-selected methylation sites within the genomic material contained in the test animal-derived product sample; and (b) comparing the test methylation profile determined in (a) with a panel of predetermined reference methylation profiles of the same biological taxon of the test animal from which the product sample derives, wherein each of the predetermined reference methylation profiles is from a different reference animal and/or different supplier, wherein if the test methylation profile of (a) is significantly similar to one of the predetermined reference methylation profiles, the test animal-derived product sample is confirmed of originating from a first supplier from which a first reference animal with the predetermined reference profile is obtained.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present invention relates to a method of determining the supplier from which a test animal-derived product sample originates, the method comprising the steps of: (a) determining a test methylation profile of one or more pre-selected methylation sites within the genomic material contained in the test animal-derived product sample; and (b) comparing the test methylation profile determined in (a) with a panel of predetermined reference methylation profiles of the same biological taxon of the test animal from which the product sample derives, wherein each of the predetermined reference methylation profiles is from a different reference animal and/or different supplier, wherein if the test methylation profile of (a) is significantly similar to one of the predetermined reference methylation profiles, the test animal-derived product sample is confirmed of originating from a first supplier from which a first reference animal with the predetermined reference profile is obtained.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure pertains to an in vitro method for the diagnostic classification of cancer based on the biological state of specific genomic sites. The disclosure provides a method that allows for a classification of a tumour sample obtained from a patient by analysing a multitude, preferably genome wide, collection of gene sites, combining the biological state of the analysed gene sites into a biological state pattern and comparing with pre-determined biological state patterns pertaining to different cancer types or tumour species. The disclosure is in particular useful for classifying cancer e.g. of the central nervous system, such as brain tumour samples and tumours of the spinal cord, since these are characterized by a large variety of distinct tumour species which have different prognostic values and require a developed treatment regime for each species in the clinical context. However, other cancers could similarly profit from the disclosure, for example sarcomas.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G06F 9/50 - Allocation of resources, e.g. of the central processing unit [CPU]
• G06F 15/78 - Architectures of general purpose stored program computers comprising a single central processing unit
• G06N 3/02 - Neural networks
• G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]
• G06N 20/20 - Ensemble learning
• G16B 40/20 - Supervised data analysis
• G16B 40/30 - Unsupervised data analysis